4. Primary lateral sclerosis Clinical trials / Disease details
Clinical trials : 7 / Drugs : 17 - (DrugBank : 9) / Drug target genes : 19 - Drug target pathways : 32
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04825613 (ClinicalTrials.gov) | June 1, 2021 | 25/3/2021 | Individual Patient Expanded Access IND to Treat Primary Lateral Sclerosis | Individual Patient Expanded Access IND to Evaluate the Safety and Efficacy of HB-adMSCs for the Treatment of Primary Lateral Sclerosis | Primary Lateral Sclerosis, Adult, 1 | Biological: HB-adMSCs | Hope Biosciences Stem Cell Research Foundation | Hope Biosciences | Temporarily not available | 18 Years | N/A | Male | United States |